STOCK TITAN

Neuronetics: Madryn reports approximately 21.6% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Neuronetics, Inc. (STIM) reports that Madryn Asset Management, LP and affiliated reporting persons beneficially own an aggregate 20,809,561 common shares, or approximately 21.6% of the class. The ownership calculation uses 96,478,311 shares outstanding as of November 12, 2026; the company states that 18,750,000 shares were issued and sold in its underwritten public offering that day.

The Madryn Parties have registration rights for Consideration Shares, including piggyback rights subject to customary cutbacks. If the company receives a qualifying Shelf Notice after the March 2, 2026 amendment's effective date, it must prepare and file a resale registration statement as promptly as practicable and no later than five business days after filing its 2025 Form 10-K. The Madryn Parties also agreed not to acquire additional equity or convertible debt securities, and to vote shares they own at the 2026 annual meeting in line with the board's recommendation on certain proposals. Their offering-related lock-up runs through 30 days after the final prospectus; Avinash Amin's separate lock-up runs 90 days.

Beneficial ownership 20,809,561 shares Aggregate reported by Madryn Asset Management, LP and affiliated reporting persons.
Ownership percentage 21.6% Approximate percentage of Neuronetics common stock beneficially owned in aggregate.
Shares outstanding 96,478,311 shares As of November 12, 2026; used for the ownership calculation.
Public offering shares issued and sold 18,750,000 shares Neuronetics underwritten public offering on November 12, 2026.
Madryn lock-up period 30 days After the final prospectus date, ending at close of business; subject to customary exceptions.
Avinash Amin lock-up period 90 days After the final prospectus date, ending at close of business.
Resale registration filing deadline Five business days After the company files its 2025 Form 10-K, if it receives a qualifying Shelf Notice.
beneficial ownership regulatory
"beneficially own an aggregate 20,809,561 common shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
piggyback rights technical
"piggyback rights subject to customary cutbacks"
Shelf Notice technical
"receives a qualifying Shelf Notice after the ... amendment's effective date"
Registrable Securities technical
"resale of all Registrable Securities then beneficially owned"
lock-up agreement financial
"entered into a lock-up agreement with the representative of the underwriters"
A lock-up agreement is a contract that prevents company insiders and early investors from selling their shares for a fixed period after a stock sale, often after an initial public offering. It matters to investors because it temporarily limits the number of shares that can hit the market, which can keep the share price steadier; when the lock-up ends, a sudden increase in available shares can create extra volatility, revealing insiders’ confidence or lack thereof.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Neuronetics (STIM) shares do Madryn and its affiliates beneficially own?

Madryn Asset Management, LP and affiliated reporting persons reported aggregate beneficial ownership of 20,809,561 shares, approximately 21.6% of Neuronetics common stock. The ownership calculation uses 96,478,311 shares outstanding as of November 12, 2026.

When must Neuronetics file a resale registration statement for Madryn?

If Neuronetics receives a Shelf Notice after the effective date of the March 2, 2026 amendment, it must prepare and file a registration statement covering resale of the Madryn Parties' then-beneficially-owned Registrable Securities as promptly as practicable and within five business days after filing its 2025 Form 10-K.

What do the Neuronetics offering lock-up agreements restrict?

During the applicable period, the agreements restrict offering, pledging, selling, lending or otherwise transferring shares or convertible securities; hedging or other transactions transferring economic ownership; registration demands or exercises; and public disclosure of an intention to take those actions. Madryn's agreement is subject to customary exceptions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





64131A105

(CUSIP Number)
Matthew Girandola
Chief Compliance Officer, 330 Madison Avenue, Floor 33
New York, NY, 10017
(646) 560-5490

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
11/12/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


MADRYN ASSET MANAGEMENT, LP
Signature:/s/ Matthew Girandola
Name/Title:Matthew Girandola / Chief Compliance Officer
Date:11/16/2026
MADRYN HEALTH PARTNERS II, LP
Signature:/s/ Matthew Girandola
Name/Title:Matthew Girandola / Chief Compliance Officer
Date:11/16/2026
MADRYN HEALTH PARTNERS II (CAYMAN MASTER), LP
Signature:/s/ Matthew Girandola
Name/Title:Matthew Girandola / Chief Compliance Officer
Date:11/16/2026
MADRYN HEALTH ADVISORS II, LP
Signature:/s/ Matthew Girandola
Name/Title:Matthew Girandola / Chief Compliance Officer
Date:11/16/2026
MADRYN HEALTH ADVISORS GP II, LLC
Signature:/s/ Matthew Girandola
Name/Title:Matthew Girandola / Chief Compliance Officer
Date:11/16/2026
MADRYN SELECT OPPORTUNITIES, LP
Signature:/s/ Matthew Girandola
Name/Title:Matthew Girandola / Chief Compliance Officer
Date:11/16/2026
MADRYN SELECT ADVISORS, LP
Signature:/s/ Matthew Girandola
Name/Title:Matthew Girandola / Chief Compliance Officer
Date:11/16/2026
MADRYN SELECT ADVISORS GP, LLC
Signature:/s/ Matthew Girandola
Name/Title:Matthew Girandola / Chief Compliance Officer
Date:11/16/2026
Comments accompanying signature:
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named above agree to the joint filing on behalf of each of them of this Statement on Schedule 13D with respect to the Common Stock.

Keep reading